Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38658724 | 0.85 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL16974723 | 0.79 | HSD17B10 (0.31) | — | |
| SCHEMBL21248540 | 0.76 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL38657618 | 0.76 | FFAR2 (0.30) | — | |
| SCHEMBL24607699 | 0.75 | HSD17B10 (0.33) | — | |
| SCHEMBL286067 | 0.75 | — | — | |
| SCHEMBL21272763 | 0.73 | MEN1 (0.40) | — | |
| SCHEMBL20609051 | 0.71 | TSHR (0.42) | — | |
| SCHEMBL16600526 | 0.71 | HRH3 (0.32) | — | |
| SCHEMBL22683067 | 0.71 | VNN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| CN-115413278-B | Pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2025-01-10 | — | — | CN | claimed |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2023-07-13 | — | — | US | claimed |
| CN-115413278-A | Novel pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2022-11-29 | — | — | CN | claimed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | claimed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-115413278-B | Pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2025-01-10 | — | — | CN | disclosed |
| EP-3766882-B1 | PHTHALAZINE ISOXAZOLE ALKOXY DERIVATIVES, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-115996908-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2023-04-21 | — | — | CN | disclosed |
| CN-115413278-A | Novel pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2022-11-29 | — | — | CN | disclosed |
| US-11512089-B2 | Substituted [1,2,4]triazolo[3,4-a]phthalazines as modulators of GABAA receptor activity | Shanghai SIMR Biotechnology Co., Ltd (CN) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | LRRK2, PARK7, SLC29A2 | CYP11B1 4585/4885CYP11B2 4644/4885 |
| US-11512089-B2 | Substituted [1,2,4]triazolo[3,4-a]phthalazines as modulators of GABAA receptor activity | GABRA5, GABRA4, GABRA3 | CYP11B1 193/4885CYP11B2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.